nach oben

Breast Cancer Research

Erschienen in:

01.10.2010 | Viewpoint

Ferroportin and hepcidin: a new hope in diagnosis, prognosis, and therapy for breast cancer

verfasst von: Igor P Pogribny

Erschienen in: Breast Cancer Research | Ausgabe 5/2010

Einloggen, um Zugang zu erhalten

Abstract

Breast cancer is the most prevalent malignancy in women. The success of breast cancer treatment relies on the ability to detect the disease and correct molecular abnormalities at an early stage of disease development. A recent article describes a marked decrease in the levels of ferroportin in breast cancer. More importantly, the presented results demonstrate convincingly the incredible diagnostic and prognostic value of ferroportin and hepcidin gene expression in breast cancer and suggest that determination of these two molecular markers may be used as guidance toward individualized therapy for breast cancer patients.

Hentze MW, Muckenthaler MU, Galy B, Camaschella C: Two to tango: regulation of mammalian iron metabolism. Cell. 2010, 142: 24-38. 10.1016/j.cell.2010.06.028.CrossRefPubMed

Richardson DR, Ponka P: The molecular mechanisms of the metabolism and transport of iron in normal and neoplastic cells. Biochim Biophys Acta. 1997, 1331: 1-40.CrossRefPubMed

Kwok JC, Richardson DR: The iron metabolism of neoplastic cells: alterations that facilitate proliferation?. Crit Rev Oncol Hematol. 2002, 42: 65-78. 10.1016/S1040-8428(01)00213-X.CrossRefPubMed

Shpyleva SI, Tryndyak VP, Kovalchuk O, Starlard-Davenport A, Chekhun VP, Beland FA, Pogribny IP: Role of ferritin alterations in human breast cancer cells. Breast Cancer Res Treat. 2010

Lieghr JG, Jones JS: Role of iron in estrogen-induced cancer. Curr Med Chem. 2001, 8: 839-849.CrossRef

Kabat GC, Rohan TE: Does excess iron play a role in breast carcinogenesis? An unresolved hypothesis. Cancer Causes Control. 2007, 18: 1047-1053. 10.1007/s10552-007-9058-9.CrossRefPubMed

Huang X: Does iron have a role in breast cancer?. Lancet Oncol. 2008, 9: 803-807. 10.1016/S1470-2045(08)70200-6.CrossRefPubMedPubMedCentral

Jiang XP, Elliot RL, Head JF: Manipulation of iron transported genes results in the suppression of human and mouse mammary adenocarcinomas. Anticancer Res. 2010, 30: 759-765.PubMed

Pinnix ZK, Miller LD, Wang W, D'Agostino R, Kute T, Willingham MC, Hatcher H, Tesfay L, Sui G, Di X, Torti SV, Torti FM: Ferroportin and iron regulation in breast cancer progression and prognosis. Sci Transl Med. 2010, 2: 43ra56

10.

Fleming MD: The regulation of hepcidin and its effects on systemic and cellular iron metabolism. Hematology Am Soc Hematol Educ Program. 2008, 151-158.

11.

Franchini M, Montagnana M, Lippi G: Hepcidin and iron metabolism: from laboratory to clinical implications. Clin Chim Acta. 2010, 411: 1565-1569. 10.1016/j.cca.2010.07.003.CrossRefPubMed

12.

Richardson DR, Kalinowski DS, Lau S, Jansson PJ, Lovejoy DB: Cancer cell iron metabolism and the development of potent chelators as anti-tumour agents. Biochim Biophys Acta. 2009, 1790: 702-717.CrossRefPubMed

13.

Courselaud B, Pigeon C, Inoue Y, Inoue J, Gonzalez FJ, Leroyer P, Gilot D, Boudjema K, Guguen-Guillouzo C, Brissot P, Loréal O, Ilyin G: C/EBPalpha regulates hepatic transcription of hepcidin, an antimicrobial peptide and regulator of iron metabolism. Cross-talk between C/EBP pathway and iron metabolism. J Biol Chem. 2002, 277: 41163-41170. 10.1074/jbc.M202653200.CrossRefPubMed

14.

Sow FB, Alvarez GR, Gross RP, Satoskar AR, Schlesinger LS, Zwilling BS, Lafuse WP: Role of STAT1, NF-kappaB, and C/EBPbeta in the macrophage transcriptional regulation of hepcidin by mycobacterial infection and IFN-gamma. J Leukoc Biol. 2009, 86: 1247-1258. 10.1189/jlb.1208719.CrossRefPubMed

Titel: Ferroportin and hepcidin: a new hope in diagnosis, prognosis, and therapy for breast cancer
verfasst von: Igor P Pogribny
Publikationsdatum: 01.10.2010
Verlag: BioMed Central
Erschienen in: Breast Cancer Research / Ausgabe 5/2010
Elektronische ISSN: 1465-542X
DOI: https://doi.org/10.1186/bcr2641

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Ferroportin and hepcidin: a new hope in diagnosis, prognosis, and therapy for breast cancer

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2010

Mapping the cellular and molecular heterogeneity of normal and malignant breast tissues and cultured cell lines

A multigene predictor of metastatic outcome in early stage hormone receptor-negative and triple-negative breast cancer

A novel approach for the generation of genetically modified mammary epithelial cell cultures yields new insights into TGFβ signaling in the mammary gland

RARα1 control of mammary gland ductal morphogenesis and wnt1-tumorigenesis

17-allyamino-17-demethoxygeldanamycin treatment results in a magnetic resonance spectroscopy-detectable elevation in choline-containing metabolites associated with increased expression of choline transporter SLC44A1 and phospholipase A2

Silencing of the IKKε gene by siRNA inhibits invasiveness and growth of breast cancer cells

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie